Why This JPMorgan Analyst Says Now Is the Tim...

Despite a rough past week for the healthcare sector, pharmaceuticals and biotech stocks have outperformed the S&P 500 this year. Investors have gotten excited over cancer treatment breakthroughs for Moderna, Merck and Revolution Medicines—plus regulatory shakeups at the FDA. But ...  Show more

On this week’s episode of WSJ’s Take On the Week, host Miriam Gottfried and guest host Aaron Back, editor of WSJ’s Heard on the Street, preview the upcoming employment and inflation releases in advance of the Federal Open Market Committee’s September policy meeting. They analyze ...  Show more

For YMB listeners, here’s a special presentation of WSJ’s Take On the Week: Co-hosts Gunjan Banerji, lead writer for Live Markets, and Telis Demos, Heard on the Street’s banking and money columnist, cut through the noise and dive into markets, the economy, and finance—the big tra ...  Show more

 On this edition of Wall Street Week, Saira Malik, Nuveen CIO tells us about election risks to markets around the world. Sharmin Mossavar-Rahmani, Goldman SachsWealth Management Group CIO makes the case for overweight us equites. Robert Rubin, Former US Treasury Secretary tells u ...  Show more

One of the most iconic brands in financial television returns for today's issues and today's world. On this edition of Wall Street Week, Saira Malik, Nuveen CIO & Bob Michele, JPMorgan Asset Management CIO & Global Head of Fixed Income wrap up a turbulent week in the markets. Tom ...  Show more

On this edition of Wall Street Week, Rebecca Patterson, Former Bridgewater Chief Investment Strategist & Mona Mahajan, Edward Jones Senior Investment Strategist wrap up the week in the markets. Gillian Tett, Financial Times Editor-at-Large on why we should all be paying attention ...  Show more